Table 1.
Bacterial Coinfections in Patients Admitted to the Hospital with COVID-19
| Refs | Location | No. of patients | Prevalence of bacterial coinfection | Proportion of patients who received antibacterial therapy |
|---|---|---|---|---|
| [13] | Michigan, USA (38 hospitals) | 1705 | 3.5% | 57% (median: 3 days) |
| [14] | London, England (2 hospitals) | 1396 | 2.7% | 98%a |
| [15] | Barcelona, Spain (1 hospital) | 989 | 2.5% | NR |
| [16] | The Netherlands (4 hospitals) | 925 | 0.8% | 60% (median: 2 days) |
| [17] | London, England (2 hospitals) | 836 | 3.2% | NR |
| [18] | Chicago, USA (1 hospital) | 321 | 1.2% | 69% |
| [19] | Liverpool, England (1 hospital) | 195 | 2.6% | NR |
| [20] | Hong Kong (1 hospital) | 147 | 2.7% | 35%b |
| [21] | Hangzhou, China (1 hospital) | 101 | 0% | NR |
| [22] | Paris, France (1 hospital) | 101 (ICU patients only) | 19.8% | 58% |
Abbreviations: ICU, intensive care unit; No., number; NR, not reported.
a
The denominator for this proportion includes 37 patients with bacterial coinfection and 100 randomly selected patients without bacterial coinfection.
b
Of the 35% of patients who received empirical antibiotics, 37% received them for more than 1 week.